Vascular diseases

$4.16 Billion Neurovascular Intervention Devices Market - Global Forecast to 2027 - Acquisitions and Partnerships as a Part of the Growth Strategy

Retrieved on: 
Wednesday, March 10, 2021

DUBLIN, March 10, 2021 /PRNewswire/ -- The "Neurovascular Intervention Devices Global Market - Forecast To 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 10, 2021 /PRNewswire/ -- The "Neurovascular Intervention Devices Global Market - Forecast To 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Neurovascular Intervention Devices global market is expected to grow at a high single digit CAGR to reach $4,167.4 million by 2027.
  • As a result of rapid advances, there is the great expansion in the potential therapeutic application for neurovascular diseases.
  • Neurovascular Interventional devices are used to treat intracranial aneurysm, ischemic stroke, arteriovenous malformation, carotid stenosis and other diseases like intracranial stenosis, dural fistula.

Peripheral Interventions Market Revenue to Cross USD 11.5 Bn by 2027: Global Market Insights Inc.

Retrieved on: 
Tuesday, March 9, 2021

An increasing multitude of disorders including peripheral artery diseases and cancer has further contributed to the market expansion.

Key Points: 
  • An increasing multitude of disorders including peripheral artery diseases and cancer has further contributed to the market expansion.
  • Thus, with the rising geriatric pool and incidence of atherosclerosis, the market will showcase substantial growth during the forecast years.
  • Technological advancements to offer enhanced care and improved treatment outcomes will offer unprecedented opportunities for the peripheral interventions market value in the coming years.
  • Guidewires segment in the peripheral interventions market accounted for USD 400 million in 2020 led by the increasing use of guidewire technology in complex lesions during interventional procedures.

InspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United States

Retrieved on: 
Wednesday, February 24, 2021

TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC), a leading Contract Research Organization (CRO) to conduct the clinical trial for its CGuard Carotid Stent System in the United States.

Key Points: 
  • TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC), a leading Contract Research Organization (CRO) to conduct the clinical trial for its CGuard Carotid Stent System in the United States.
  • HCC is ideally suited to manage this trial having supported clinical trial operations for a variety of products and indications, including with multiple carotid intervention procedures, stated Marvin Slosman, InspireMDs CEO.
  • This will be the first U.S.-based study of CGuard and our opportunity to demonstrate its potential for the prevention of stroke caused by carotid artery disease in patients in the United States.
  • We look forward to working with InspireMD on this pivotal trial of the CGuard System to help establish a new standard of care for the management of carotid artery disease and stroke prevention.

Evasc Neurovascular Announces First Neuro Product Approved in French Forfait Innovation Program

Retrieved on: 
Tuesday, February 23, 2021

Evasc Neurovascular is proud to announce its successful application to Frances Ministry of Health (Haute Autorit de la Sant, HAS) Forfait Innovation (FI) program for the eCLIPs device, published in its official journal December 23, 2020 - https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000042722732 .

Key Points: 
  • Evasc Neurovascular is proud to announce its successful application to Frances Ministry of Health (Haute Autorit de la Sant, HAS) Forfait Innovation (FI) program for the eCLIPs device, published in its official journal December 23, 2020 - https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000042722732 .
  • View the full release here: https://www.businesswire.com/news/home/20210222005015/en/
    The eCLIPs device is the first neuro device that has gained Forfait Innovation approval and funding (Graphic: Business Wire)
    The Forfait Innovation program grants clinical trial funding to evaluate CE marked devices that are deemed to be truly innovative (not simply incremental developments) and offer significant clinical benefit, filling an unmet medical need.
  • The eCLIPs device is the first neuro device that has gained FI approval and funding.
  • Evasc Neurovascular is a privately-held medical device company focused on the development of disruptive endovascular treatments for cerebral aneurysms.

$ 156.6 Million Growth in Global Endovenous Ablation Devices Market During 2021-2025 | Featuring Key Vendors Including AngioDynamics Inc., AtriCure Inc., and Eufoton srl | Technavio

Retrieved on: 
Monday, February 22, 2021

NEW YORK, Feb. 22, 2021 /PRNewswire/ -- Tavio announces the release of its latest report on the endovenous ablation devices market.

Key Points: 
  • NEW YORK, Feb. 22, 2021 /PRNewswire/ -- Tavio announces the release of its latest report on the endovenous ablation devices market.
  • The market is segmented by product (EVLT devices, RFA devices, and NTNT devices) and geography (North America, Europe, Asia, and ROW).
  • The increasing prevalence of CVI (chronic venous insufficiency) is one of the prime factors driving the growth of the market.
  • "Growing demand for MI endovenous ablation procedures and Technological advances in endovascular ablation devices will further boost market growth during the forecast period", says a senior analyst at Technavio.

Study Confirms Elucid’s AI Software Accurately Estimates Lesion-Specific Ischemia Compared to Standard of Care

Retrieved on: 
Thursday, February 18, 2021

The study, entitled Coronary plaque assessment of Vasodilative capacity by CT angiography effectively estimates fractional flow reserve demonstrates that Fractional Flow Reserve (FFR) assessment derived from non-invasive plaque morphology using Elucids software is highly accurate as compared to invasive FFR.

Key Points: 
  • The study, entitled Coronary plaque assessment of Vasodilative capacity by CT angiography effectively estimates fractional flow reserve demonstrates that Fractional Flow Reserve (FFR) assessment derived from non-invasive plaque morphology using Elucids software is highly accurate as compared to invasive FFR.
  • These measurements were fed into Elucids computational neural networks to accurately estimate ischemia.
  • The combination of Computed Tomography-based Fractional Flow Reserve (FFRct) and plaque morphology provides the clearest overview of myocardial ischemia in order to determine treatment options for a patient.
  • Leveraging Elucids software, the study demonstrated a strong level of sensitivity and specificity relative to invasive FFR.

Shockwave Intravascular Lithotripsy FDA Approved to Treat Advanced Heart Disease

Retrieved on: 
Tuesday, February 16, 2021

With this approval, IVL is now commercially available in the United States to treat problematic calcium in the coronary arteries, which can reduce blood flow in the heart.

Key Points: 
  • With this approval, IVL is now commercially available in the United States to treat problematic calcium in the coronary arteries, which can reduce blood flow in the heart.
  • As coronary artery disease progresses, plaque in the arterial wall often evolves into calcium deposits, which narrow the artery and restrict blood flow.
  • Intravascular Lithotripsy uses sonic pressure waves, also known as shockwaves, that pass through soft arterial tissue and preferentially disrupt calcified plaque by creating a series of micro-fractures.
  • Shockwave is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated.

Tactile Medical to Participate in Upcoming Investor Conferences in February and March

Retrieved on: 
Tuesday, February 9, 2021

MINNEAPOLIS, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (Tactile Medical) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced that management will participate in the following upcoming investor conferences:

Key Points: 
  • MINNEAPOLIS, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (Tactile Medical) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced that management will participate in the following upcoming investor conferences:
    Management will participate in a virtual fireside chat on Wednesday, February 17 at 9:30 a.m. Eastern Time.
  • Audio webcasts of the presentations will be accessible under the Events & Webcasts section of the Company's investor relations website at http://investors.tactilemedical.com .
  • Tactile Medical is a leader in developing and marketing at-home therapy devices that treat chronic swelling conditions such as lymphedema and chronic venous insufficiency.
  • Tactile Medicals Mission is to help people suffering from chronic diseases live better and care for themselves at home.

Chronic Venous Ulceration (CVU) Epidemiology Forecast Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 4, 2021

This 'Chronic Venous Ulceration (CVU) - Epidemiology Forecast - 2030' report delivers an in-depth understanding of the disease, historical and forecasted Chronic Venous Ulceration (CVU) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Key Points: 
  • This 'Chronic Venous Ulceration (CVU) - Epidemiology Forecast - 2030' report delivers an in-depth understanding of the disease, historical and forecasted Chronic Venous Ulceration (CVU) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of Venous Ulcers, Diagnosed Prevalent Cases of Venous Ulcers , Diagnosed Prevalent Cases of Venous Leg Ulcers, Type-specific Distribution of Venous Ulcers, Gender-specific Distribution of Venous Ulcers and Age-specific Distribution of Venous Ulcers in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
  • Depending on the duration for healing, venous ulcers can be of two types: Acute Venous Ulcers, and Chronic Venous Ulcers.
  • The diagnosed prevalent cases of Acute Venous Ulcers and Chronic Venous Ulcers in the United States were 1,407,345 and 1,223,206 in 2020 .

InspireMD Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China

Retrieved on: 
Wednesday, February 3, 2021

TEL AVIV, Israel, Feb. 03, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today announced a transaction intended to achieve distribution of CGuard EPS in mainland China.

Key Points: 
  • TEL AVIV, Israel, Feb. 03, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today announced a transaction intended to achieve distribution of CGuard EPS in mainland China.
  • Following announcement of the transaction the Chinese partners plan to initiate the process of securing registration with Chinese regulatory authorities to establish distribution.
  • One of our pillars of growth is global expansion of CGuard EPS into significant markets of opportunity and this step in China establishes a foundation for our overall Asia plan.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.